Related Experiment Videos
Soft-tissue swelling in two neonates during prostaglandin E1 therapy
Pediatric Cardiology
|January 1, 1986
Summary
Prostaglandin E1 (PGE1) therapy in neonates can cause significant soft tissue swelling in extremities. This peripheral edema, along with bone changes, is a potential complication of long-term PGE1 treatment.
Area of Science:
- Pediatric Cardiology
- Neonatal Pharmacology
- Medical Complications
Background:
- Congenital heart defects necessitate interventions like prostaglandin E1 (PGE1) to maintain ductal patency.
- PGE1 is crucial for managing certain critical congenital heart diseases in neonates.
- The study focuses on adverse effects observed during prolonged PGE1 administration.
Observation:
- Two neonates with severe congenital heart disease received prolonged intravenous PGE1.
- One neonate had hypoplastic right heart syndrome; the other had tetralogy of Fallot with pulmonary atresia.
- Both neonates developed significant soft tissue swellings in their extremities.
Findings:
- Cortical hyperostosis was observed in both patients, though limited.
- Marked soft tissue edema was a prominent finding in all extremities.
- Skin biopsy revealed edematous changes and arteriolar wall abnormalities.
- These peripheral changes appeared after weeks of PGE1 treatment.
Implications:
- Peripheral hard edema is identified as a potential complication of prostaglandin E1 therapy.
- Understanding the pathophysiology of PGE1-induced edema is crucial for patient management.
- This finding expands the known spectrum of adverse effects associated with PGE1 treatment in neonates.